VESUGEN

Description

Synthetic Peptide for Vascular Bioregulator Research

Technical Overview

Vesugen 20mg is a synthetic peptide compound developed for laboratory research involving vascular endothelial gene expression and short-peptide bioregulator activity, receptor interaction analysis, and controlled experimental investigation. In research settings, this peptide is commonly utilized for studying endothelial cell signaling, angiogenesis-related transcription factor activity, and related biochemical mechanisms.

Vesugen is a Khavinson-class short-peptide bioregulator with the sequence L-Lys-L-Glu-L-Asp (KED), originally derived from analysis of vascular tissue extracts. Short peptides in this class are hypothesized to interact with DNA in a sequence-specific manner, modulating gene expression in tissues from which they were originally isolated.

Researchers use Vesugen in endothelial cell-culture systems to study tissue-specific gene-regulation hypotheses, vascular bioregulator pharmacology, and the Khavinson framework of complementary peptide-DNA interactions. It is commonly compared with other tripeptide bioregulators in mechanistic studies.

This compound is synthesized using established solid-phase peptide synthesis methods and purified through reversed-phase HPLC to achieve analytical purity suitable for laboratory assays, binding studies, and analytical applications. The lyophilized material is supplied for reconstitution per established laboratory protocols and is intended as a reference material in controlled research environments.

Specifications

Compound Name: Vesugen
Strength: 20mg
Purity: ≥ 99% (HPLC Verified)
Appearance: Lyophilized Peptide Powder
Format: Research Compound
Reconstitution: Suitable for laboratory assay preparation.

Notice

Provided as a reference material for scientific investigation only.